Executive Officers
Martin McGlynn, President and Chief Executive Officer
Martin McGlynn joined StemCells, Inc. in January of 2001 as President and Chief Executive Officer and was elected to our Board of Directors on February 6, 2001. Mr. McGlynn has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson, Ireland Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and Chief Executive Officer of Pharmadigm, Inc., a private, venture capital-backed company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC).
Ann Tsukamoto, Ph.D., Executive Vice President, Research and Development
Ann Tsukamoto, Ph.D., was appointed Executive Vice President, Research and Development in September 2008. She previously served as Vice President, Research and Development. Dr. Tsukamoto has ~20 years experience in stem cell biology and was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and she played a leading role in the launch of the clinical research program for the hematopoietic stem cell. Under her direction at StemCells Inc., the scientific team has discovered the human central nervous system stem cell, a population of human liver engrafting cells and a candidate pancreas stem cell. Dr. Tsukamoto received her Ph.D. from the University of California, Los Angeles and did postdoctoral research with Dr. Harold Varmus at the University of California, San Francisco where she worked on the wnt-1 gene, which is a key player in the stem cell self-renewal pathway. Dr. Tsukamoto is an inventor on six issued U.S. patents related to the human hematopoietic stem cell.
Rodney Young, Chief Financial Officer & VP, Finance and Administration
Rodney Young joined StemCells, Inc. in September 2005. He is responsible for the financial and administrative functions of the Company, as well as for managing investor relations and the Company's overall relationship with the financial community. Mr. Young was formerly Chief Financial Officer and a Director of Extropy Pharmaceuticals, Inc., a private pharmaceutical company focused on developing drugs for pediatric indications, where he was responsible for all financial and administrative functions. Before joining Extropy, Mr. Young was Managing Director and head of healthcare corporate finance in Europe for SG Cowen Securities, and prior to that, he spent more than a decade at Lehman Brothers, where he was a senior investment banker in both the healthcare and mergers & acquisitions groups. Mr. Young earned his BA and MBA degrees from the University of Chicago.
Stewart Craig, Ph.D., Senior Vice President, Development and Operations
Stewart Craig, Ph.D., joined StemCells, Inc. in September 2008 to lead the process design and engineering, GMP manufacturing operations, regulatory affairs, quality assurance, facilities and supply chain management functions. Dr. Craig brings over 15 years of experience in the cell therapy field and was most recently Vice President and Chief Technology Officer of Progenitor Cell Therapy, LLC (PCT). Prior to that was chief operating officer of Xcyte Therapies, Inc. and has also held senior management positions Osiris Therapeutics, Inc., and SyStemix, Inc. Dr. Craig earned his B.Sc. (Hons) in Biochemistry and his Ph.D. in Physical Biochemistry from the University of Newcastle upon Tyne, United Kingdom. He is a member of the International Society for Cell Therapy, and was previously a member of the U.S. Pharmacopeia Cell and Gene Therapy Advisory Panel and the International Society for Pharmaceutical Engineering. Dr. Craig is an inventor on five issues U.S. patents and three international patents related to cell therapies.
Ken Stratton , General Counsel
Ken Stratton joined StemCells, Inc. as General Counsel in February 2007. His primary responsibilities include overseeing the Company’s legal operations and advising the Company and its management and directors on various compliance matters. He also serves as corporate secretary. In March 2008, he assumed responsibilities for the Human Resources function. Mr. Stratton was formerly Deputy General Counsel at Threshold Pharmaceuticals, Inc., and prior to that was Senior Legal Counsel for the vascular business unit of Medtronic, Inc., an international medical device manufacturer. Prior to joining industry, Mr. Stratton was a business attorney in private practice for ten years handling both transactional and litigation matters with corporate law firms in San Francisco and Palo Alto. He earned both his J.D. and M.B.A. in finance from New York University and his B.A. from the University of Pennsylvania.
|
|
